Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes News and Research
Diabetes News
Tresiba approved in the UK
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="DCUK NewsBot" data-source="post: 797813" data-attributes="member: 106455"><p>Insulin degludec is an ultra long-acting basal insulin developed by Novo Nordisk under the brand name Tresiba. It has been approved in the UK for children and teenagers between the ages of one and 17. The suitability of Tresiba was assessed in the BEGIN YOUNG 1 trial, the first to look at the long-term safety of insulin degludec in children with type 1 diabetes. The trial was conducted by injecting Tresiba once a day as part of a daily basal-bolus regimen. Tresiba was injected along with insulin aspart, a fast-acting insulin also developed by Novo Nordisk. The results of the trial indicated that Tresiba contributed to long-term glycemic control, making it an effective option for type 1 diabetes management amongst children and teenagers aged between one and 17. Type 1 diabetes affects around 24,000 children in England. Type 1 diabetes is far more common in children than type 2, with 96 per cent of children with diabetes being type 1 diabetic. However, more and more children are developing type 2 diabetes. Dr. Nandu Thalange, paediatric endocrinologist at Norfolk and Norwich University Hospital and lead investigator for the BEGIN YOUNG 1 trial, said: "When treating children and adolescents with diabetes, getting patients to target while minimising side effects is a key priority. However, a large proportion of younger people with diabetes are unable to achieve this effectively with current insulin options. "Longer acting insulins like insulin degludec, which was shown to be effective in the BEGIN YOUNG 1 trial, provide an additional option for treating children and adolescents with diabetes. "Clinicians can be reassured that insulin degludec offers an effective treatment option for younger people with diabetes, as well as for adults in the general diabetes population."</p><p></p><p><strong><a href="http://www.diabetes.co.uk/news/2015/mar/tresiba-approved-in-the-uk-91708645.html" target="_blank">Continue reading...</a></strong></p></blockquote><p></p>
[QUOTE="DCUK NewsBot, post: 797813, member: 106455"] Insulin degludec is an ultra long-acting basal insulin developed by Novo Nordisk under the brand name Tresiba. It has been approved in the UK for children and teenagers between the ages of one and 17. The suitability of Tresiba was assessed in the BEGIN YOUNG 1 trial, the first to look at the long-term safety of insulin degludec in children with type 1 diabetes. The trial was conducted by injecting Tresiba once a day as part of a daily basal-bolus regimen. Tresiba was injected along with insulin aspart, a fast-acting insulin also developed by Novo Nordisk. The results of the trial indicated that Tresiba contributed to long-term glycemic control, making it an effective option for type 1 diabetes management amongst children and teenagers aged between one and 17. Type 1 diabetes affects around 24,000 children in England. Type 1 diabetes is far more common in children than type 2, with 96 per cent of children with diabetes being type 1 diabetic. However, more and more children are developing type 2 diabetes. Dr. Nandu Thalange, paediatric endocrinologist at Norfolk and Norwich University Hospital and lead investigator for the BEGIN YOUNG 1 trial, said: "When treating children and adolescents with diabetes, getting patients to target while minimising side effects is a key priority. However, a large proportion of younger people with diabetes are unable to achieve this effectively with current insulin options. "Longer acting insulins like insulin degludec, which was shown to be effective in the BEGIN YOUNG 1 trial, provide an additional option for treating children and adolescents with diabetes. "Clinicians can be reassured that insulin degludec offers an effective treatment option for younger people with diabetes, as well as for adults in the general diabetes population." [b][url="http://www.diabetes.co.uk/news/2015/mar/tresiba-approved-in-the-uk-91708645.html"]Continue reading...[/url][/b] [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes News and Research
Diabetes News
Tresiba approved in the UK
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…